Peptides for Inflammation: What Is Prescribed, How It Works, and What to Rule Out

A trigger, whether a torn fiber, a bacterial fragment or an irritated gut lining, is detected by receptors on local cells, which switch on master transcription factors, the best known being NF-κB. NF-κB directs the cell to manufacture cytokines: TNF-α, IL-1β, IL-6, IL-8. The cytokines recruit white cells, open local vessels and sensitize nerve endings. That is the redness, heat, swelling and pain.

Most of the peptides on this page are described as acting on that switch rather than on the downstream products. A steroid suppresses immunity broadly; an NSAID blocks cyclo-oxygenase and so blocks prostaglandins. Neither touches NF-κB directly.

In a healthy response the cascade resolves: cytokine production shuts down, recruited cells are cleared, and repair takes over. The cases that bring people here are the ones where that does not happen: a tendon sore for a year, a gut that flares repeatedly, joints that ache with no clear injury, or a general sense of being inflamed that a blood test may or may not confirm.

Persistent, low-level inflammation is the pattern associated with excess adipose tissue, metabolic disease, poor sleep and aging. Its clinical marker is usually high-sensitivity C-reactive protein (hsCRP), and much of it is driven by fat mass rather than any local injury. The SELECT trial's prespecified analysis in Circulation in 2026 reported that semaglutide reduced hsCRP by 37.8 percent at 104 weeks in adults with cardiovascular disease and overweight or obesity, with the reduction evident by four to eight weeks, before major weight loss. The SURMOUNT-1 post hoc analysis in the Journal of the American College of Cardiology in 2026 reported hsCRP reductions of 36.9 to 54.6 percent across tirzepatide doses at 72 weeks. If the inflammation is metabolic, the peptide with human trial data is semaglutide or tirzepatide, not anything in the table above.

The intestinal lining is one cell thick and sits between the bloodstream and the largest bacterial population in the body. When it is irritated, by NSAIDs, alcohol, infection or inflammatory bowel disease, the immune cells beneath it see bacterial products and the cascade fires. This is why the literature on KPV and BPC-157 is so concentrated on the gut.

KPV is a tripeptide, lysine-proline-valine, the last three amino acids of alpha-melanocyte-stimulating hormone (α-MSH), a hormone the body already makes. The review in Endocrine Reviews in 2008 describes this C-terminal tripeptide as carrying much of the parent hormone's anti-inflammatory activity without its pigmentation effects.

The mechanism most often cited is direct interference with NF-κB. A 2012 paper in the International Journal of Physiology, Pathophysiology and Pharmacology reported, in cultured human bronchial epithelial cells, that KPV entered the nucleus, stabilized IκBα (the protein that holds NF-κB inactive) and blocked nuclear import of the p65 subunit, with dose-dependent reductions in IL-8 and eotaxin. In the gut, a 2008 paper in Gastroenterology reported that KPV is carried into intestinal epithelial and immune cells by the PepT1 transporter, reduced NF-κB activation and cytokine output there, and reduced inflammation in two mouse colitis models. A second 2008 paper in Inflammatory Bowel Diseases reported earlier recovery and reduced inflammatory infiltrates with KPV in two colitis models, and a 2013 PLoS One paper reported reduced brain inflammation after a single dose in a mouse traumatic brain injury model.

There are no randomized human trials of KPV. The FDA's own summary, in a listing it later withdrew, was that it had not identified any human exposure data for KPV by any route. Prescribing rests on the mechanism above and clinical experience.

KPV suits the person whose inflammation is not attached to a specific injury: the diffuse ache, the gut that reacts to everything, the skin that flares. It is the one product here whose primary described action is anti-inflammatory rather than reparative. It is prescribed alone at /peptide/kpv and inside KLOW and FORTIFY; the reference is what is KPV.

BPC-157 is a fifteen-amino-acid fragment of a protein found in human gastric juice. Its better-known literature is tendon and muscle repair, but its original and largest body of work is gastrointestinal protection, which is where its relevance to inflammation lies. The review in Current Pharmaceutical Design in 2011 covers animal studies describing protection of the gut lining against NSAID and alcohol injury and effects in inflammatory bowel models; a 2018 review in the same journal sets that beside the tendon, ligament, muscle and bone findings and argues they share a vascular mechanism.

The 2006 Achilles detachment study in the Journal of Orthopaedic Research and the 2014 Molecules paper on growth hormone receptor expression in tendon fibroblasts are why BPC-157 is the peptide reached for when inflammation and tissue damage are happening in the same place.

There are no randomized controlled trials of BPC-157 in humans. Early-phase human work has been conducted for inflammatory bowel indications, and the FDA's advisory committee reviewed it for ulcerative colitis in July 2026; the vote is covered below.

BPC-157 suits gut-driven inflammation, or the inflammatory phase of an injury that has not resolved. It is prescribed alone at /peptide/bpc-157 and is in KLOW, FORTIFY and GLOW; the full reference is what is BPC-157.

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from the thymus. It is a different kind of tool: it does not suppress an inflammatory signal, it is described as improving the quality of an immune response. The review in the Annals of the New York Academy of Sciences in 2010 calls it a "regulator of regulators" for its described effects on Toll-like receptor signaling, dendritic cell maturation and T-cell differentiation; a 2020 review in the World Journal of Virology summarizes the same literature.

This is the one peptide here with a genuine human trial record, and that record is mixed. In chronic hepatitis B, a randomized trial in Hepatology in 1998 and a 2008 meta-analysis in Antiviral Research compared it with interferon; the 2026 Cochrane review pooled ten randomized trials with 1,349 participants and rated the certainty of evidence very low for every outcome except serious adverse events. In sepsis, the ETASS trial in Critical Care in 2013 reported 28-day mortality of 26.0 versus 35.0 percent in 361 patients, just short of significance, while the larger TESTS phase 3 trial in the BMJ in 2025, with 1,089 patients, reported 23.4 versus 24.1 percent and found no clear evidence of benefit. A retrospective series in Clinical Infectious Diseases in 2020 reported lower mortality in severe COVID-19, but that was observational. None of these was in general inflammation.

Thymosin alpha-1 suits the person whose inflammatory picture comes with immune dysregulation: recurrent infections, a chronic viral history, or a physician's judgment that the immune response itself is the problem. It is prescribed alone at /peptide/thymosin-alpha-1 and inside FORTIFY; the reference is what is thymosin alpha-1.

TB-500 is a synthetic fragment of thymosin beta-4, a protein present in almost every cell. It is here because it is inside KLOW and GLOW and because its literature includes a specific anti-inflammatory mechanism: Experimental Eye Research in 2007 reported thymosin beta-4 suppressing NF-κB in corneal cells, and a 2011 paper in the FASEB Journal reported it inhibiting TNF-α-induced NF-κB activation and IL-8 expression. A 2002 paper in Experimental Eye Research reported faster corneal healing and decreased inflammation in an alkali-injury animal model. The broader repair literature is reviewed in Trends in Molecular Medicine in 2005.

Thymosin beta-4 has some randomized human data, a placebo-controlled dose study in healthy volunteers in the Annals of the New York Academy of Sciences in 2010 and a phase 2 trial of an eye-drop formulation in severe dry eye in Cornea in 2015, but those were the full protein or an ophthalmic preparation. There are no randomized trials of injectable TB-500 for inflammation. It is prescribed at /peptide/tb-500 for soft-tissue repair.

GHK-Cu is a copper-binding tripeptide found in human plasma, best known for skin and collagen, and it is inside KLOW and GLOW. Its inflammation literature is mostly lung: a 2016 paper in Oncotarget reported reduced lipopolysaccharide-induced acute lung injury in mice, a 2020 paper in Life Sciences described protection in bleomycin-induced pulmonary fibrosis through anti-oxidative and anti-inflammatory pathways, and a 2022 paper in Frontiers in Molecular Biosciences reported reduced smoke-induced emphysema and inflammation in animals. Human data for GHK-Cu is topical and small, a 1994 paper in Wound Repair and Regeneration on diabetic ulcers; there are no randomized trials of injectable GHK-Cu for inflammation. It is prescribed alone at /peptide/ghk-cu for skin and connective tissue.

KLOW combines GHK-Cu, KPV, BPC-157 and TB-500 in one vial. The logic is that an injury which will not settle has two problems at once: an inflammatory phase that has not resolved and tissue that has not repaired. KPV addresses the first through the NF-κB mechanism; BPC-157 and TB-500 address the second through angiogenesis, cell migration and actin regulation; GHK-Cu contributes its described effects on connective tissue.

There are no trials of the combination; a 2026 study in Joint Diseases and Related Surgery examined BPC-157 and TB-500 together in a rat Achilles model, the closest the literature comes. KLOW is the usual prescription when the inflammation has an address, a specific tendon, joint or muscle. The reference is what is KLOW.

FORTIFY combines thymosin alpha-1, BPC-157, KPV and LL-37. It is the prescription when inflammation comes with immune involvement: recurrent infections, a post-viral picture, or a physician's judgment that the immune system is under-responding as well as over-firing.

LL-37 is the only human cathelicidin, an antimicrobial peptide reviewed in Biochimica et Biophysica Acta in 2006; its human evidence is two randomized placebo-controlled trials of a topical preparation in venous leg ulcers, in Wound Repair and Regeneration in 2014 and 2021. One point of honesty: a 2007 paper in Nature reported that LL-37 can couple with self-DNA to activate plasmacytoid dendritic cells, a mechanism implicated in psoriasis, which is why a physician asks about autoimmune skin disease before prescribing FORTIFY. There are no trials of the four-peptide combination. The reference is what is FORTIFY.

GLOW is BPC-157, GHK-Cu and TB-500 without KPV. It is the prescription when the complaint is in the skin or connective tissue and the goal is repair rather than damping a systemic signal. If the picture is more "inflamed" than "damaged," KLOW is usually the better conversation. The reference is what is GLOW.

Between 2023 and early 2026, KPV, BPC-157, TB-500, injectable GHK-Cu and LL-37 all sat in Category 2 of the FDA's interim 503A bulk drug substances list, the category for nominated substances flagged as raising significant safety concerns. The FDA's stated concerns were immunogenicity and peptide impurities for BPC-157, TB-500, GHK-Cu and LL-37, and the absence of any human exposure data for KPV.

On 15 April 2026 the FDA announced it was removing twelve peptides from Category 2, effective within seven days, because the nominations had been withdrawn by the nominators. BPC-157, KPV, TB-500 (thymosin beta-4 fragment), injectable GHK-Cu and cathelicidin LL-37 were all among the twelve. The FDA's safety-risk page now lists all five under substances nominated but withdrawn, and its interim category list, updated 14 May 2026, shows none of them in Category 1, 2 or 3. Removal lifts the safety-risk designation; it does not, by itself, place a substance on the positive 503A Bulks List.

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV and TB-500 and voted 8 to 6, with one abstention in each case, to recommend adding each, as the free base and the acetate, to the 503A Bulks List. The uses reviewed were ulcerative colitis for BPC-157, wound healing and inflammatory conditions for KPV, and wound healing for TB-500. The FDA's own scientists had recommended against inclusion for every peptide on the two-day agenda; the committee voted the other way on six of seven.

A committee vote is a recommendation, not a decision. The FDA issues its own determination afterwards through rulemaking, and as of September 2026 that determination is pending.

Neither was on the July agenda. The FDA has said the committee will consider GHK-Cu, cathelicidin LL-37, dihexa, PEG-MGF and Melanotan II at a meeting before the end of February 2027. Until then they are no longer flagged and not yet reviewed for the positive list.

Thymosin alpha-1 left Category 2 in September 2024 after its nomination was withdrawn, so it was not part of the April 2026 action. On 4 December 2024 the Pharmacy Compounding Advisory Committee voted 4 in favor and 17 against placing thymosin alpha-1 (free base) on the 503A Bulks List, and 4 to 17 against the acetate. The uses reviewed were hepatitis B and C, HIV, COVID-19, depressed vaccine response, several cancers, sepsis, COPD and chronic fatigue syndrome; members voting no said there was no compelling evidence of clinical effectiveness and safety for those uses. The FDA has not issued a final rule, thymosin alpha-1 appears in none of the three categories on the 14 May 2026 list, and it is not on the slate for early 2027.

None of the peptides on this page is currently in Category 2 or otherwise restricted. KPV, BPC-157 and TB-500 await final FDA action on a positive recommendation; GHK-Cu and LL-37 are scheduled for review; thymosin alpha-1 received a negative recommendation in 2024 that the FDA has not acted on. All remain legal to prescribe and compound. None is FDA approved, and the blends have no regulatory status of their own; the FDA regulates the bulk substances, not the brand name. Are peptides FDA approved covers the general picture.

On the WADA Prohibited List in effect for 2026, BPC-157 is named under S0, non-approved substances, prohibited at all times, and thymosin beta-4 and its derivatives, TB-500 by name, are listed under S2.3, growth factors and growth factor modulators. The 2027 list, effective 1 January 2027, carries the same entries. KPV, GHK-Cu and thymosin alpha-1 are not named, but S0 covers any substance without regulatory approval for human use, so a tested athlete should treat every compounded peptide as a question for their anti-doping body.

Most of what is reported early is injection-site effects settling in, not the underlying problem changing. Some people notice nothing at all in this window, which is normal; there is no trial-established timeline in humans, so an absence of change at two weeks means nothing either way.

This is where people describe background ache and stiffness easing and, later, a clearer sense of what activity is tolerated. It is the window in which tissue-level change would be expected if it occurs, based on the animal timelines for BPC-157 and TB-500, and it is why refills run on a 28-day rhythm. Treatment is long-term; your physician sets the direction at each refill.

Gut symptoms are usually described as responding earlier than joint or tendon symptoms: KPV and BPC-157 act on the intestinal lining directly, whereas a chronic tendon needs tissue to change. A diffuse systemic picture is the slowest and least predictable, and the one most likely to have a metabolic driver.

Bloodwork is not routinely required before KPV, BPC-157, KLOW, FORTIFY or GLOW; your physician decides based on your history. Where the complaint is unexplained inflammation, a physician will often want a baseline before starting, because unexplained raised markers deserve a cause.

High-sensitivity CRP is the general marker most worth having at baseline, because it has the clearest link to metabolic and cardiovascular risk and is the one the GLP-1 trials measured. A complete blood count and, where the history suggests it, a metabolic panel and thyroid markers round out the picture; for thymosin alpha-1 and FORTIFY, a physician may want a white cell differential. Because there is no trial-established effect on any marker for the compounded peptides, the most useful monitoring is your own: a baseline hsCRP, the same test after two or three refills, and a plain record of what activity is tolerated. At-home blood testing covers hormone, metabolic and thyroid markers without a lab visit.

Most commonly injection-site reactions: redness, mild soreness, occasional bruising. Some people report early nausea or light-headedness. There is no established interaction list for KPV, BPC-157 or the blends, which is why a physician reviews every medication you take. Stop and contact your physician for any reaction that is severe, spreading, or involves difficulty breathing, and for any new rash on FORTIFY given the LL-37 note above.